J Pharmacol Toxicol Methods
January 2023
Histamine is strongly associated with the onset of allergic conjunctivitis. The most recent cloned histamine H receptor antagonist is highly expected as a new therapeutic drug candidate. As a model for a therapeutic drug targeting the histamine H receptor, a mouse model in which conjunctivitis symptoms are induced by instilling 4-methylhistamine, a histamine H receptor agonist, has been reported.
View Article and Find Full Text PDFJ Pharmacol Toxicol Methods
January 2022
Allergic conjunctivitis is one of the most common immune diseases in the field of ophthalmology. The number of patients suffering from allergic conjunctivitis has been increasing, and there is still a strong need for development of therapeutic agents for this disease. In drug development, the utmost important point to improve the success probability is to accurately single out good compounds in the early stage of drug development.
View Article and Find Full Text PDF